CorMedix Sees Heron Deal Savings of Up to $60 Million by 2027
Key Facts
On November 9, 2026, CorMedix announced a definitive agreement to acquire substantially all of Heron Therapeutics’ assets and assume certain liabilities, in a deal unanimously approved by the boards of both companies. The company estimated related operating cost savings of about $45 million to $60 million annually on a run-rate basis by the end of 2027. It said most of the savings would come from eliminating duplicate commercial, administrative and general, and public company expenses. CorMedix is also counting on additional revenue from Heron’s portfolio, expecting a contribution of $125 million to $150 million over full-year 2027. Chief Executive Joseph Todisco said the deal would effectively double the company’s annual product revenue, excluding DefenCath, if it closes as expected.
The announced consideration comprises $145 million in cash and 14,583,333 CorMedix common shares, along with contingent payments of up to $55 million tied to ZYNRELEF sales in 2028, as well as royalties on sales of specified products. The structure combines a cash payment and shares, with an additional portion dependent on future sales. To fund part of the deal, CorMedix entered into a term credit facility providing up to $150 million in non-dilutive financing. The company expects to draw $75 million from the facility upon closing. Borrowed financing will therefore be among the sources funding the closing, alongside the cash and shares specified in the agreement.
The deal adds four marketed products to CorMedix’s portfolio: ZYNRELEF, APONVIE, CINVANTI and SUSTOL. The products are used in hospitals, ambulatory surgery centers and infusion centers, expanding the company’s presence in institutional care settings. CorMedix estimated that Heron products generated about $150 million in net product revenue during the twelve months ended September 30, 2026. The revenue outlook for the acquired assets is $125 million to $150 million for full-year 2027. Todisco said the expected contribution would roughly double the company’s annual product revenue excluding DefenCath, provided the deal closes.
The deal comes as Heron reported total net revenue of $35.3 million in the third quarter of 2026, compared with $38.2 million in the third quarter of 2025 and $37.7 million in the second quarter of 2026. In results for the same period, CorMedix reported consolidated revenue of $54.5 million, exceeding the market consensus of $51.2 million, but posted a net loss of $14.7 million. DefenCath sales were about $17.2 million in the third quarter. The company said the transition to the post-TDAPA period beginning July 1, 2026, led to lower net pricing. These figures place revenue from the acquired products within a broader portfolio facing changes in DefenCath pricing.
In the market, CorMedix shares rose 4.5% in premarket trading on Monday, November 9, following the deal announcement, according to an Investing.com report. CRMD shares closed at $5.30 on November 11, 2026, according to EL7 data. Among other developments in the company’s update, it expected an FDA decision in the first quarter of 2027 on its application to expand REZZAYO’s use for the prevention of invasive fungal diseases; the application had received priority review. The Heron deal is expected to close in the first quarter of 2027, subject to regulatory approvals, Heron shareholder approval and customary closing conditions. After closing, attention will turn to the products’ revenue contribution and whether the estimated operating savings are realized by year-end.